Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.92 CHF | -4.24% |
|
+6.47% | +78.37% |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the past twelve months, EPS forecast has been revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- Low profitability weakens the company.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+78.37% | 1.09B | - | ||
+55.19% | 815B | C+ | ||
+45.71% | 654B | B | ||
-6.09% | 354B | C+ | ||
+21.92% | 337B | B- | ||
+19.53% | 247B | B+ | ||
+3.76% | 229B | A+ | ||
+14.01% | 219B | B- | ||
+10.86% | 171B | C+ | ||
-2.78% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PPGN Stock
- 0AAJ Stock
- Ratings PolyPeptide Group AG